B+
Bull case
18%
Probability
Target price
$6.25
Analysis reference price unavailable
Analysis 2026-06-03 · RankAlpha Sentiment Codex
PRLD
Prelude TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that PRLD has turned its strategic reset into visible execution: PRT12396 is in Phase 1, PRT13722 remains on track for a mid-2026 IND and 2H 2026 initiation, and cash now extends into Q2 2028 after the May financing [#SEC-8K-2026-05-12] [#10-K-2026-03-10]. That creates multiple shots on goal without a near-term financing spiral.
Posture
Defensive
Lead driver
Sentiment
What changed
News driver: Insider Buying : Prelude Therapeutics ( NASDAQ : PRLD ) Director Acquires 2 , 815 , 315 Shares of Stock.
What can break
Coverage is thin; the post-print analyst revisions are informative but not yet a durable validation signal [#PR-EARNINGS-2026-05-16].
Momentum
90
Value
41
Sentiment
25
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.50 · Bull $6.25 · Bear $1.50Analysis 2026-06-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.00
Why
Momentum90 · Δ7d -3.9
Value41 · Δ7d 0.0
Sentiment25 · Δ7d +6.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • News driver: Insider Buying : Prelude Therapeutics ( NASDAQ : PRLD ) Director Acquires 2 , 815 , 315 Shares of Stock.
- • Sentiment remains the lead driver in the composite, 7D delta +6.2.
Contradictions & invalidation
- • Coverage is thin; the post-print analyst revisions are informative but not yet a durable validation signal [#PR-EARNINGS-2026-05-16].
- • PRT12396 is early; any enrollment, safety, or mechanistic setback would quickly push the stock back toward cash-and-option-value trading [#SEC-8K-2026-05-12].
- • The bear case is that investors still do not have human efficacy data, so the stock remains a timing-and-execution trade rather than a de-risked development asset.
Catalyst clock
2026-05-12
PRT12396 Phase 1 enrollment is the next concrete execution check
Lead driver: Sentiment · See AI snapshot
Momentum
90
9% active weight
Current posture
7d trendSoftening
Δ7d
-3.9
Δ21d
-2.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
25
62% active weight
Current posture
7d trendImproving
Δ7d
+6.2
Δ21d
+8.9
Why this grade
Composite grade F. Momentum 90.4 / Value 41.2 / Sentiment 24.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-03. Scenario method
Most likely
B
Base case
57%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-06-03 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-06-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$532.21M
Beta
0.88
Shares Out
79.65M
P/E (TTM) · Derived
-5.2
P/S (TTM)
14.61
P/FCF (TTM) · Derived
-21.92
Rev YoY
+41.0%
EPS YoY
-65.6%
Gross Margin
+92.9%
Op Margin
-300.6%
Net Debt
-$85.43M
Current Ratio
4.07
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data